Source: International Congress 2017 – PG2 Multidrug-resistant tuberculosis management in settings with a low tuberculosis incidence 
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Payam Nahid (San Francisco, United States of America). New and repurposed drugs for MDR-TB patients. International Congress 2017 – PG2 Multidrug-resistant tuberculosis management in settings with a low tuberculosis incidence 

Member's Comments

No comment yet.

Related content which might interest you: New and repurposed TB drugs use in children and adolescents with M/XDR-TB Source: International Congress 2017 – Treatment of multi-drug-resistant tuberculosis (MDRTB): where are we now? Year: 2017 Bacteriological conversion in XDR-TB and RR-TB patients with fluoroquinolone resistance treated with and without new and repurposed anti-TB drugs in Azerbaijan prisons Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018 New and repurposed drugs Source: Eur Respir Monogr 2018; 82: 179-204 Year: 2018 The drug armamentarium for MDR-TB cases Source: International Congress 2017 – How to manage difficult tuberculosis cases: diagnosis and treatment Year: 2017 Novel drug regimens against MDR-TB Source: International Congress 2016 – The problem of multidrug-resistant tuberculosis Year: 2016 New guidelines to manage MDR-TB Source: School Course 13 Year: 2013 New anti-tuberculosis drugs and regimens: 2015 update Source: ERJ Open Res 2015; 1: 00010-2015 Year: 2015 New drugs and drug regimens in the treatment of chronic and MDR-TB - what is on the horizon? Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005 New perspectives in MDR-TB management Source: International Congress 2016 – China Session II Year: 2016 Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 New anti-tuberculosis drugs for special populations: a difficult-to-address issue Source: Eur Respir J 2016; 48: 957-958 Year: 2016 Spreading of resistance to group A anti-tuberculosis drugs among TB patients in Astana city Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018 New approaches to MDR/XDR TB chemotherapy in children and adolescents Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019 MDR-TB and XDR-TB: drug resistance and treatment outcomes Source: Eur Respir J 2009; 34: 778 Year: 2009 Management of drug resistant pulmonary TB. New problems and perspectives Source: Annual Congress 2009 - Multi/extensively-drug resistant tuberculosis Year: 2009 Linezolid in the treatment of patients with MDR TB and XDR TB Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013